US4446154A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders
Assignee: Thomas Jefferson University
•
Filing: 1982-09-30
•
Granted: 1984-05-01
•
Expires: 2002-09-30
Abstract
Abstract A novel acute care cerebral support system and method for treating severly ischemic brains is disclosed wherein an oxygenated nutrient emulsion is circulated through at least a portion of the ventriculo-subarachnoid spaces. The nutrient emulsion contains an oxygenatable non-aqueous component, an aqueous nutrient component, an emulsification component, and other components which render physiologic acceptability to the nutrient emulsion. The disclosed system and method have been shown to effectively exchange oxygen, carbon dioxide, glucose, and other metabolites in severely stroked brains. Significant restoration of oxidative metabolism and electrographic activity result from the disclosed treatment. Methods for producing the nutrient emulsion and a system for delivering that emulsion to the cerebrospinal pathway are also disclosed. Additionally, novel diagnostic methods for diagnosing the physiologic state of hypoxic-ischemic and other diseased neurologic tissue during treatment are provided.
Inventors
- 👤 Jewell L. Osterholm
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 18:41
CPC Classifications
A; A61; A61M; A61M3/00; A61M3/02; A61M3/0204; A61M3/0212; A61M2202/00; A61M2202/04; A61M2202/0464; A61M2202/0468; A61M2202/0476; A61M2205/00; A61M2205/36; A61M2205/3653; A61M2210/00; A61M2210/06; A61M2210/0693
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
88 words
An artificial central nervous system, cerebrospinal pathway treatment liquid for treating hypoxic-ischemic cerebrospinal tissue, comprising, an aqueous emulsion containing: (a) a non-aqueous fluorocarbon oxygen transfer component for selectively combining with oxygen and for transferring oxygen to said tissues to be treated; (b) an aqueous nutrient component comprising at least essential electrolytes for said tissue; and (c) an emulsification component for permitting the emulsification of said nutrient means with said oxygen transfer means; and at least one treatment agent selected from the group consisting of steroids and amino acids.
Claim 2
Dependent Claim
88 words
An artificial central nervous system, cerebrospinal pathway treatment liquid for treating hypoxic-ischemic cerebrospinal tissue, comprising, an aqueous emulsion containing: (a) a non-aqueous fluorocarbon oxygen transfer component for selectively combining with oxygen and for transferring oxygen to said tissues to be treated; (b) an aqueous nutrient component comprising at least essential electrolytes for said tissue; and (c) an emulsification component for permitting the emulsification of said nutrient means with said oxygen transfer means; and at least one treatment agent selected from the group consisting of steroids and amino acids.
Claim 3
Dependent Claim
16 words
The invention of claim 1 wherein said aqueous nutrient means further comprises sodium, potassium and chloride.
Claim 4
Dependent Claim
14 words
The invention of claim 2 wherein said aqueous phase further comprises magnesium and calcium.
Claim 5
Dependent Claim
16 words
The invention of claim 1 wherein said nutrient liquid has pH of between 6.8 and 7.5.
Claim 6
Dependent Claim
18 words
The invention of claim 1 wherein said nutrient component further comprises a carbohydrate component containing at least glucose.
Claim 7
Dependent Claim
12 words
The invention of claim 5 wherein said carbohydrate component further comprises glucose.
Claim 8
Dependent Claim
14 words
The invention of claim 1 wherein said treatment component further comprises an antiobiotic agent.
Claim 9
Dependent Claim
11 words
The method of claim 7 wherein said antibiotic agent is bacitracin.
Claim 10
Dependent Claim
13 words
The invention of claim 1 wherein said nutrient component further comprises carbon dioxide.
Claim 11
Dependent Claim
20 words
The invention of claim 1 wherein said nutrient liquid, after oxygen saturation, has a pO 2 in excess of 400.
Claim 12
Dependent Claim
20 words
The invention of claim 10 wherein said nutrient liquid, after oxygen saturation, has a pO 2 in excess of 600.
Claim 13
Dependent Claim
21 words
The invention of claim 1 wherein said nutrient liquid, after oxygen saturation, has an osmolarity of between about 298 and 317.
Claim 14
Dependent Claim
22 words
The invention of claim 1 wherein said treatment liquid further comprises an amino acid component having at least one essential amino acid.
Claim 15
Dependent Claim
29 words
The invention of claim 13 wherein said essential amino acid is selected from the group consisting of: D--Glutamic Acid L--Glutamine DL--Serine D--Threonine D--Lysine D--Valine D--Leucine DL--Isoleucine D--Phenylalanine DL--Tyrosine D--Methionine
Claim 16
Dependent Claim
17 words
The invention of claim 14 wherein each of said essential amino acids comprise said amino acid component.
Claim 17
Dependent Claim
13 words
The invention of claim 1 wherein said nutrient component further comprises a pyruvate.
Claim 18
Dependent Claim
22 words
The invention of claim 1 wherein said nutrient component further comprises a carbohydrate derivative which is a metabolic precursor of a pyruvate.
Claim 19
Dependent Claim
14 words
The invention of claim 1 wherein said nutrient component further comprises a bicarbonate ion.
Claim 20
Dependent Claim
25 words
The invention of claim 1 wherein said nutrient liquid has an osmolarity of between 318 and 325 and is thereby useful to treat cerebral edema.
Claim 21
Dependent Claim
13 words
The invention of claim 1 wherein said treatment liquid further comprises a steroid.
References Cited (Backward Citations)
US3482575A
Cited
US3516410A
Cited
US3583387A
Cited
US3626950A
Cited
US3669116A
Cited
US3669094A
Cited
US3690323A
Cited
US3946731A
Cited
US3753865A
Cited
US3823091A
Cited
US3941119A
Cited
US3989843A
Cited
US3894541A
Cited
US4163734A
Cited
US4148314A
Cited
US4173654A
Cited
US4173224A
Cited
US4110474A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-05-01 | 1987-10-31 | 1988-05-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-05-01 | 1991-10-31 | 1992-05-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-05-01 | 1995-10-31 | 1996-05-01 | $7700.00 | Window Closed / Lapsed |